{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"0","value":"0.25"},{"groupId":"OG001","spread":"0","value":"0.25"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"6"}],"units":"Participants"}],"description":"Plasma concentrations of TG-0054 were determinate by validated LC-MS/MS method.","dispersionType":"Standard Deviation","groups":[{"description":"TG-0054: 2.24 mg/kg TG-0054 administrated via 15-min IV infusion(allow a maximum of six leukapheresis sessions)","id":"OG000","title":"TG-0054 (2.24 mg/kg)"},{"description":"TG-0054: 3.14 mg/kg TG-0054 administrated via 15-min IV infusion(allow a maximum of six leukapheresis sessions)","id":"OG001","title":"TG-0054 (3.14 mg/kg)"}],"paramType":"MEAN","populationDescription":"According to the protocol, blood samples for PK assessment of TG-0054 were obtained from 6 consenting patients in each arm on study Day 1 at pre-dose, end of infusion, and 1 hr, 3 hr, 6 hr, 9 hr, 12 hr, 24 hr and 36 hrs after infusion.","reportingStatus":"POSTED","timeFrame":"36 hrs after infusion","title":"Time at Which Maximum Plasma Concentration is Observed (Tmax) of TG-0054 in 12 Consented Patients With MM, NHL or HD.","type":"SECONDARY","unitOfMeasure":"hr"}